Anti-Il31 Mab Mcs Lot #1283563

Verify with FDA CVM →

5,270 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
5,270
Total Reports
360
Deaths Reported
680.0%
Death Rate

Active Ingredients

Anti-Il31 Mab Mcs Lot #1283563

Administration Routes

SubcutaneousUnknownOtherOralSubconjunctivalSublingualIntramuscularAuricular (Otic)Intrathoracic

Species Affected

Dog 5,268
Cat 2

Most Affected Breeds

Retriever - Labrador 436
Terrier - Bull - American Pit 314
Terrier - Yorkshire 291
Shih Tzu 272
Bulldog - French 244
Chihuahua 222
Retriever - Golden 197
Shepherd Dog - German 187
Crossbred Canine/dog 170
Boxer (German Boxer) 149

Most Reported Reactions

Vomiting 994
Lack of efficacy - NOS 833
INEFFECTIVE, ATOPY CONTROL 751
Lethargy (see also Central nervous system depression in 'Neurological') 632
Diarrhoea 535
Anorexia 303
Lethargy (see also Central nervous system depression in Neurological) 275
Hives (see also 'Skin') 273
Seizure NOS 257
Not eating 248
Decreased appetite 217
Pruritus 213

Outcome Breakdown

Ongoing
3,548 (67.3%)
Recovered/Normal
757 (14.4%)
Outcome Unknown
597 (11.3%)
Euthanized
194 (3.7%)
Died
166 (3.1%)
Recovered with Sequela
11 (0.2%)

Data Summary

Metric Value
Total adverse event reports 5,270
Reports involving death 360
Case-fatality rate (reported events) 680.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Anti-Il31 Mab Mcs Lot #1283563 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 5,270 adverse event reports referencing Anti-Il31 Mab Mcs Lot #1283563, including 360 reports in which the animal died — a 680.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Anti-Il31 Mab Mcs Lot #1283563. Reported administration routes include Subcutaneous, Unknown, Other, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Anti-Il31 Mab Mcs Lot #1283563 reports are Dog (5,268 reports), Cat (2 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (436), Terrier - Bull - American Pit (314), Terrier - Yorkshire (291) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Anti-Il31 Mab Mcs Lot #1283563 are Vomiting (994), Lack of efficacy - NOS (833), INEFFECTIVE, ATOPY CONTROL (751), Lethargy (see also Central nervous system depression in 'Neurological') (632). Of the 5,273 reports with a coded outcome, Ongoing is the leading category at 67.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Anti-Il31 Mab Mcs Lot #1283563.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial